Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide - PubMed
3 months ago
- #pharmacotherapy
- #obesity
- #meta-analysis
- Tirzepatide and semaglutide are leading pharmacological options for obesity treatment.
- A network meta-analysis (NMA) compared the efficacy of tirzepatide and semaglutide in weight reduction and glycemic control.
- 28 RCTs with 34,367 participants (39.6% women, mean age 57.8 years) were included.
- Tirzepatide showed superior results in weight reduction (6.10% more than semaglutide), BMI reduction (1.71 kg/m² more), and waist circumference reduction (2.89 cm more).
- Tirzepatide also outperformed semaglutide in improving glycemic parameters, including HbA1c (0.33% more reduction) and fasting blood glucose (10.39 mg/dL more reduction).
- Conclusion: Tirzepatide is superior to semaglutide in both weight loss and glycemic improvement.